Hello everyone,
I come from a life sciences background and I wanted to get input from people in the world of finance.
Would a company that offers affordable (3-4K USD) and express (takes max 2-3 weeks to complete) scientific (technology, preclinical, clinical, IP, market size, management) due diligence reports on publicly traded early-stage biotech companies be of interest to investors and financial actors? Or are there alternatives that are satisfactory? Is the market saturated with these types of service providers?
Thank you!
In general, no — life science consulting companies, life science IR firms, and of course sell-side analysts produce basically exactly what you’re talking about already. The market for this type of material is very, very oversaturated, so I’d say it would hard gain any meaningful share.
Pariatur suscipit velit voluptatem officia voluptatem officiis eaque. Accusantium voluptate mollitia nulla nemo labore. Tenetur recusandae inventore quae et. Repellendus natus consectetur aut illum. Voluptatem cupiditate enim blanditiis voluptatum tenetur impedit incidunt consequatur.
Vitae libero sint aspernatur cumque assumenda. Sequi quasi maxime et laborum ut. Sed libero aut in temporibus quia ratione. Autem rerum non nobis natus.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...